secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005063
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics reports Q4 revenue $44.4M; ends Janssen deal, cuts workforce to ~220
--------------------------------------------------------------------------------

- Cash and investments $441.2M plus $38.5M receivables; total ~$475M as of Dec 31, 2022.
- Q4 2022 revenue $44.4M from collaborations; R&D expense $87.2M, G&A $21.6M.
- Janssen collaboration terminated effective Apr 3, 2023; all programs discontinued.
- Restructuring reduces headcount to ~220; expects $12-16M severance charges in Q1 2023.
- IND planned mid-2023 for FT522 in B-cell lymphoma; FT825/ONO-8250 IND expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/0000950170-23-005063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/fate-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer